NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.500
+0.170 (12.78%)
At close: Jul 6, 2026, 4:00 PM EDT
1.490
-0.010 (-0.67%)
After-hours: Jul 6, 2026, 4:45 PM EDT
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,155,856
Market Cap
34.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 0 | - |
| Jun 30, 2023 | 7 | -10 | -58.82% |
| Jun 30, 2022 | 17 | 0 | - |
| Jun 30, 2021 | 17 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Evaxion | 46 |
| Senti Biosciences Holdings | 39 |
| Kyntra Bio | 34 |
| Actinium Pharmaceuticals | 25 |
| Daré Bioscience | 24 |
| Lisata Therapeutics | 21 |
| Serina Therapeutics | 16 |
NNVC News
- 7 hours ago - NanoViricides initiated with an Outperform at Noble Capital - TheFly
- 8 hours ago - NanoViricides advances towards Phase II clinical trial of NV-387 - TheFly
- 8 hours ago - As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo - Accesswire
- 7 days ago - NanoViricides granted Rare Pediatric Disease Drug designation for NV-387 - TheFly
- 7 days ago - US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher - Accesswire
- 14 days ago - NanoViricides ships NV-387 oral gummies for Phase II trials to DR Congo - TheFly
- 14 days ago - NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo - Accesswire
- 21 days ago - NanoViricides files to sell 1.33M shares of common stock for holders - TheFly